Avacta is a UK-based clinical stage biotech focused on the novel pre|CISION platform to generate peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment, which has the potential to expand the reach and reduce the systemic toxicities of highly potent cancer therapeutics.
Avacta’s growing knowledge base and expertise is cementing its leadership position in FAP-enabled biotherapeutics. Lead clinical asset, faridoxorubicin (AVA6000 or FAP-Dox) is the first of a series of pre|CISION-based modalities that have the potential to improve the therapeutic index of many highly potent yet systemically toxic oncology drugs. Other novel programmes including AVA6103 (FAP-EXd) and the dual payload peptide drug conjugates further broaden the potential utility of the pre|CISION platform. Progress into the clinic and successful clinical results over the next 18 months should provide multiple value-inflection points.
| Symbol | Primary exchanges |
| AVCT | AIM London |